Pfizer Reports Strong Q2 2025 Performance with Pipeline Advances and Raised Guidance
Key Insights
Pfizer delivered strong Q2 2025 results with $14.7 billion in revenues and 10% operational growth, driven by robust performance across its commercial portfolio including Vyndaqel, Padcev, and Eliquis.
The company raised its full-year 2025 adjusted diluted earnings per share guidance by $0.10 to $2.90-$3.10, reflecting strong operational execution and cost management initiatives.
Key pipeline advances include positive Phase III data for Elrexfio in multiple myeloma (search) showing >97% response rates and Hympavzi demonstrating 93% reduction in bleeding rates for hemophilia patients.
Pfizer delivered robust financial performance in the second quarter of 2025, reporting revenues of $14.7 billion with 10% operational growth, while advancing key pipeline programs and raising full-year earnings guidance. The pharmaceutical giant demonstrated strong execution across its commercial portfolio and research pipeline, positioning itself for continued growth despite ongoing policy uncertainties.
Strong Commercial Performance Drives Growth
The company's commercial strategy delivered impressive results across multiple therapeutic areas. The Vyndaqel family of products achieved 21% year-over-year operational growth, maintaining its position as the foundation of care for patients with ATTR cardiomyopathy (search). Pfizer continues to see strong progress in diagnosing patients and providing broad access, with the product demonstrating continued volume growth despite competitive pressures from new market entrants.
Padcev, a key oncology asset, showed exceptional performance with 38% year-over-year operational growth in the quarter. The ADC for treating locally advanced metastatic urothelial cancer (search) has secured greater than 50% market share in first-line treatment and established itself as the standard of care. The company anticipates Phase III readouts for Padcev in muscle invasive bladder cancer from two ongoing studies, which could significantly expand the addressable patient population to approximately 28,000 patients in the U.S.
Other notable performers included LORBRENA with 48% year-over-year operational growth, supported by compelling efficacy data from the CROWN study where median progression-free survival was not reached after 5 years of follow-up. The combination of Braftovi and Mektovi demonstrated 23% operational growth, with Phase III BREAKWATER trial results showing the regimen doubled median overall survival versus standard of care for treatment-naive patients with metastatic colorectal cancer (search).
Pipeline Advances Show Promise
Pfizer's research and development efforts yielded significant milestones during the quarter. Elrexfio, the company's multiple myeloma (search) treatment, continues to show encouraging clinical progress. New data from the MagnetisMM-6 study demonstrated a confirmed response rate greater than 97% with a manageable safety profile in combination with daratumumab and lorlatinib. The randomized portion of this Phase III study is enrolling well, with potential label expansion that could increase the addressable population approximately fivefold in the multiple myeloma market expected to reach $44 billion by 2030.
Sigvotatug Vedotin (SV), Pfizer's first-in-class integrin-beta 6 (search) ADC, advanced through a robust development program in non-small cell lung cancer (search). The fully enrolled Phase III study of SV monotherapy versus docetaxel in previously treated non-squamous patients is expected to deliver data next year. In the second-line plus population, the compound demonstrated a durable 31% confirmed response rate, comparing favorably to historical data with docetaxel monotherapy.
The company also reported positive Phase III data from the BASIS study evaluating Hympavzi for adults and adolescents with hemophilia A (search) or B. The study's cohort of patients with inhibitors met its primary endpoint, demonstrating a statistically significant and clinically meaningful 93% reduction in annualized bleeding rate compared to on-demand treatment in patients 12 years and older.
Strategic Business Development Expands Oncology Portfolio
Pfizer completed its licensing agreement with 3SBio (search) for SSGJ-707, a bispecific antibody targeting PD-1 (search) and VEGF (search). This addition to the company's oncology portfolio has the potential to deliver breakthroughs in PD-1 immunotherapy, addressing an established $55 billion market. With monotherapy data in advanced non-small cell lung cancer (search) presented at ASCO, the company views this as a promising cancer immunotherapy candidate that fits seamlessly within Pfizer's oncology strategy.
The company plans to announce details for Phase III programs later this year, with 707 having potential to become a backbone therapy for multiple solid tumor types where the PD-L1 (search)/VEGF (search) mechanism could have significant impact.
Financial Strength and Raised Guidance
Pfizer's financial performance reflected disciplined execution and strategic priorities. Adjusted gross margin for the second quarter was approximately 76%, while total adjusted operating expenses decreased 8% operationally versus the prior year. The company's cost improvement initiatives contributed to greater organizational efficiencies, with robust operating margins achieved during the quarter.
Based on strong year-to-date performance, Pfizer raised its full-year 2025 adjusted diluted earnings per share guidance by $0.10 to a range of $2.90 to $3.10. This increase includes absorbing a $0.20 charge for acquired in-process R&D associated with the 3SBio (search) transaction upfront payment. The company maintained its full-year revenue guidance of $61 billion to $64 billion.
The company's gross leverage improved to approximately 2.7x at the end of the second quarter, which management has set as the new target, down from 3.25x. This improved balance sheet position provides approximately $13 billion in business development capacity following the 3SBio (search) deal.
Vaccine Portfolio Development
Pfizer continues advancing its vaccine portfolio with several promising candidates. The company is preparing for a Phase III start before year-end for its second-generation C. difficile vaccine candidate, which demonstrated a fourfold increase in immune response strength compared to the first-generation vaccine. If approved, the vaccine could significantly reduce the healthcare burden of nearly 500,000 annual C. diff infections and approximately 30,000 annual deaths in the U.S.
The company also finished dosing the last patient in its Lyme disease (search) vaccine candidate study, with submission for approval expected next year if successful.